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Neurodegenerative amyloid diseases are fatal disorders representing an important human health and 
economic burden. Amongst them, nine disorders are classified as polyglutamine (polyQ) diseases, for 
which no treatment is yet available. They are all characterized by the pathological expansion of a 
poly(CAG) sequence, above a specific threshold, within the coding sequence of nine unrelated genes, 
translated in nine polyQ proteins. The polyQ expansion, the only common point, is the critical 
determinant for polyQ disease development by triggering protein aggregation into amyloid fibrils. 
More recent studies however indicate that the protein context modulates the polyQ-induced 
aggregation process and the disease phenotype.  
The objectives of my thesis are to deeper investigate the molecular determinants of the complex 
interplay between the propensity of the polyQ tract to trigger protein aggregation and the modulating 
role of non-polyQ regions in order to allow the identification of strategies to interfere with the 
pathological aggregation process. For that purpose, model polyQ proteins, referred to as BlaP-polyQ 
chimeras, based on the β-lactamase BlaP and polyQ sequences (23 – 79Q) inserted at two positions 
(197, in between or not unstructured peptides, or 216), are used and their aggregation properties are 
characterized under several conditions. 
We first observe that the polyQ length is determinant for BlaP-polyQ chimera aggregation. Indeed, 
there is a Q-threshold for the aggregation into amyloid fibrils and for fibril elongation. Above this 
threshold, the aggregation in solution and the elongation rate increase with the length of the polyQ 
tract, with an exponential rise-to-maximum and a linear regression, respectively, independently of the 
conformation of the BlaP moiety, and of the position of the polyQ tract within BlaP. Longer polyQ 
tracts are likely to have a larger conformational flexibility allowing them to more easily adopt an 
amyloid-aggregation prone conformation. However, the Q-threshold for fibril elongation is much 
lower than for fibril formation in solution: the polyQ tract requires a larger conformational flexibility 
to nucleate the formation of fibrils than to elongate them. Secondly, the Q-threshold for fibril 
formation is lower once the BlaP moiety is unfolded, and BlaP-polyQ chimeras aggregate faster into 
amyloid fibrils under conditions favoring the unfolding of the BlaP moiety. The native structure of 
BlaP is likely to impose conformational constraints to moderate and long polyQ tracts that block and 
decrease, respectively, their propensity to form fibrils. The effects of constraints decrease with the 
polyQ length. Thirdly, BlaP chimeras with the polyQ tract in position 216 have an increased 
propensity to trigger the nucleation and the elongation of amyloid fibrils compared to chimeras with 
the polyQ in position 197. Advanced studies confirm that the propensity of the polyQ tract to 
aggregate into amyloid fibrils is linked to the conformational flexibility of the polyQ tract, which 
depends on (i) the polyQ length, (ii) the location of the polyQ tract within BlaP, i.e., a terminal 
location or embedded within a protein domain, and (iii) the structural properties of the polyQ flanking 
regions. Finally, we observe that the whole region flanking the polyQ tract in position 197 at its N-
terminus has an anti-aggregating property that fully counterbalances the pro-aggregating property of 
that flanking at the C-terminus. The former imposes strong conformational constraints to the polyQ 
tract that reduce its conformational flexibility and hence its aggregation propensity. Moreover, these 
regions are likely to differently affect the solubility of the polyQ protein and hence the driving force 
for insoluble aggregation. Altogether, our data also suggest that BlaP chimeras aggregate via the 
commonly described nucleation-dependent polymerization mechanism during which the aggregation 
is first triggered by polyQ-polyQ interactions, and then a subsequent slight reorganization of the BlaP 
moiety is required for conversion of aggregates into amyloid fibrils. 
Based on these results, we should allow the development of therapeutic strategies, targeting 
specifically the molecular features of the complex interplay between the polyQ and non-polyQ 
regions during the nucleation and/or elongation of the pathological aggregation of polyQ proteins. 
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